Just a moment, the page is loading...
Welcome to the Janssen Oncology & Haematology IIS Website
Janssen Oncology
Selected Products:
Clear AllClose



Clinical Application Details


Drug:

Decitabine

Status:

Currently Accepting Clinical IIS Applications




Review decisions will be communicated approximately 10 weeks after your submission.

Decitabine is being developed as part of strategic partnerships between Janssen Pharmaceuticals and other stakeholders around the world. As such, only Janssen's investigator-initiated studies (IIS) program is represented by this portal for customers in the Asia Pacific, EMEA, and Latin America regions.

If you are a researcher residing in the United States or Canada, your IIS application will not be accepted on this website. Please email Margaret Doyle (mdoyle11@its.jnj.com) with any questions.

Please click "Submit Application" button below to proceed.